Retatrutide Weight Loss: Tracking the Triple Agonist (2026)
No drug in development pushes the scale harder than retatrutide. It is the first molecule to switch on three metabolic receptors at once — GLP-1, GIP, and glucagon — and the Phase 3 retatrutide weight loss readouts top out at a staggering 28.7% of body weight. We track every trial number, the realistic path to approval, and how Eli Lilly's candidate measures up against the drugs you can already get today.
Retatrutide at a Glance
Known in the lab as LY3437943, retatrutide is a once-weekly injectable peptide that is still investigational — it hits three metabolic hormone receptors in a single shot: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. That third lever is the whole story. Nothing else approved or in late-stage testing touches all three, and it is why retatrutide weight loss figures sit in a class of their own.
The Mechanism Behind Retatrutide Weight Loss: Three Receptors, One Shot
GLP-1 Receptor
Reduces appetite, slows gastric emptying, and improves insulin secretion. This is the same mechanism used by semaglutide (Wegovy, Ozempic) and the GLP-1 component of tirzepatide (Zepbound).
GIP Receptor
Enhances insulin sensitivity, improves fat metabolism, and works synergistically with GLP-1 to amplify weight loss. This dual action (GLP-1 + GIP) is what makes tirzepatide more effective than semaglutide alone.
Glucagon Receptor
Increases energy expenditure and promotes fat burning, particularly in the liver. This is the novel third targetthat no other approved obesity drug activates — and it may explain why retatrutide's weight loss exceeds even tirzepatide.
Stack the three effects and they compound. GLP-1 dials down appetite and slows digestion, GIP sharpens metabolic efficiency and amplifies what GLP-1 is already doing, and glucagon turns up the rate at which the body burns calories. Most GLP-1 drugs work on one side of the ledger by cutting energy intake; the glucagon arm adds energy expenditureon top. Eating less while simultaneously burning more is, in plain terms, why the retatrutide weight loss numbers look unlike anything before them.
The glucagon receptor does something else worth flagging: it actively strips fat out of the liver. That makes retatrutide a candidate worth watching for people living with metabolic dysfunction-associated steatotic liver disease (MASLD, the condition formerly filed under NAFLD). Phase 2 participants saw their liver fat drop meaningfully on the drug.
Phase 3 Trial Results
TRIUMPH-4: Obesity + Osteoarthritis
The opening Phase 3 result landed from TRIUMPH-4, a trial enrolling people who carried both obesity and knee osteoarthritis. When the late-2025 numbers dropped, they turned heads:
At the 12mg dose, the average participant shed 28.7% of their starting body weight — north of 70 pounds — and reported real relief in joint pain and mobility alongside it. Placebo barely moved the needle at 2.1%. Even the lower 9mg dose still drove 26.4% loss.
TRANSCEND-T2D-1: Type 2 Diabetes
April 2026 brought Lilly's first Phase 3 diabetes readout. On the top dose, participants cut their A1C by up to 2.0% and dropped up to 36.6 lbs. The takeaway is that retatrutide pulls double duty in type 2 diabetes — meaningful weight loss and blood-sugar control from the same weekly injection.
Upcoming Phase 3 Readouts (2026)
Seven more Phase 3 readouts are slated to roll out across the TRIUMPH and TRANSCEND programs before the year is out. They widen the lens to broader obesity groups, test extra doses (a 4mg maintenance option among them), and probe cardiovascular outcomes and metabolic liver disease. Together, these trials are the dossier Lilly needs to build a regulatory case worth filing.
How Retatrutide Compares to Tirzepatide and Semaglutide
| Feature | Retatrutide | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|---|
| Receptor Targets | GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 only |
| Max Weight Loss (trials) | ~28.7% | ~22.5% | ~15% |
| Dosing | Once weekly injection | Once weekly injection | Once weekly injection |
| Energy Expenditure | Yes (glucagon component) | Limited | Minimal |
| Liver Fat Reduction | Significant (Phase 2) | Moderate | Some |
| FDA Status | Phase 3 (multiple readouts 2026) | Approved | Approved |
| Expected Approval | 2027–2028 (estimated) | Available now | Available now |
Read these side-by-side numbers with caution. Each drug was studied in a different group of patients over different lengths of time against different endpoints, so lining them up is only ever a rough guide. A true verdict on efficacy can only come from a head-to-head trial.
Expected Timeline
Safety Data So Far
Across Phase 2 and the early Phase 3 data, retatrutide largely behaves like the rest of the GLP-1 family on safety — with a few wrinkles the glucagon arm brings to the table:
Common Side Effects (GI-related)
- Nausea — the most frequent adverse event, consistent with other GLP-1 drugs
- Diarrhea — reported more frequently than with some GLP-1-only drugs, possibly related to the glucagon component
- Vomiting — typically mild-to-moderate and decreasing over time with dose titration
- Decreased appetite — expected pharmacological effect
Glucagon-Specific Monitoring
Because glucagon raises blood sugar, there was initial concern that the glucagon component could worsen glycemic control, particularly in people with type 2 diabetes. However, Phase 3 data from TRANSCEND-T2D-1 showed the opposite: participants achieved significant A1C reductions (up to 2.0%), suggesting the GLP-1 and GIP components more than compensate for glucagon's glucose-raising effect.
Heart Rate
GLP-1 drugs are associated with small increases in resting heart rate (typically 2–4 bpm). The cardiovascular outcome trials (currently underway) will provide definitive data on retatrutide's long-term cardiovascular safety profile. Early data has not shown concerning cardiac signals.
Discontinuation Rates
In Phase 2 trials, discontinuation rates due to adverse events were higher at the highest dose (12mg) compared to lower doses, which is consistent with the broader GLP-1 class. The Phase 3 program includes a 4mg maintenance dose option, which may offer a better tolerability profile for long-term use after initial weight loss is achieved.
Which Patients Stand to Gain Most?
Patients Who Need Maximum Weight Loss
With up to 28.7% body weight loss in trials, retatrutide may be appropriate for patients with severe obesity (BMI 40+) or obesity-related comorbidities who need the most aggressive pharmacological intervention available.
Metabolic Liver Disease
The glucagon component's effect on liver fat makes retatrutide a potential option for patients with MASLD/MASH. Phase 2 data showed significant liver fat reduction, and dedicated liver trials are planned.
Patients Who Plateau on Current GLP-1 Drugs
Some patients reach a weight loss plateau on semaglutide or tirzepatide. Retatrutide's additional glucagon receptor activation and higher ceiling of efficacy could offer further weight loss for these individuals.
Obesity with Osteoarthritis
The TRIUMPH-4 trial specifically showed improvements in osteoarthritis pain and physical function alongside weight loss, suggesting retatrutide could be particularly beneficial for this large patient population.
Frequently Asked Questions
When will retatrutide be available?
Not yet, and not soon. Retatrutide is still working through Phase 3, with several readouts due across 2026, and Eli Lilly has not filed for approval. If the trials land on schedule, an FDA submission could come in late 2026 or early 2027, putting a possible launch in the 2027-2028 window. No pharmacy can fill a prescription for it today.
Is retatrutide better than Zepbound (tirzepatide)?
Phase 3 data shows retatrutide achieves higher average weight loss (~28.7%) compared to tirzepatide's trials (~22.5%). However, these are cross-trial comparisons with different patient populations. A direct head-to-head trial would be needed for definitive comparison. Retatrutide also adds the glucagon mechanism, which increases energy expenditure and liver fat reduction.
What is a triple agonist?
A triple agonist is a drug that activates three different hormone receptors simultaneously. Retatrutide activates the GLP-1, GIP, and glucagon receptors. For comparison, semaglutide (Wegovy) is a single agonist (GLP-1 only) and tirzepatide (Zepbound) is a dual agonist (GLP-1 + GIP). Each additional receptor target adds a complementary metabolic mechanism.
Will retatrutide be a pill or injection?
Retatrutide is a once-weekly subcutaneous injection, similar to Wegovy and Zepbound. There are currently no announced plans for an oral formulation. As a peptide drug, creating an oral version would require the same absorption challenges that make oral semaglutide (Rybelsus) complex.
How much weight can you lose on retatrutide?
The headline retatrutide weight loss figure comes from TRIUMPH-4: people on the 12mg dose averaged a 28.7% reduction in body weight, roughly 71 lbs. Step down to 9mg and the average was 26.4%. Your own result will depend on your starting weight, the dose you reach, and your diet and activity along the way.
Is retatrutide safe for people with type 2 diabetes?
The TRANSCEND-T2D-1 Phase 3 trial showed that retatrutide achieved significant A1C reductions (up to 2.0%) alongside weight loss in people with type 2 diabetes. Despite the glucagon component (which can raise blood sugar), the overall effect was strongly glucose-lowering, suggesting the GLP-1 and GIP components more than compensate.
Can I get retatrutide from a compounding pharmacy?
No. Retatrutide is an investigational drug that has not been approved by the FDA. It is not legally available outside of clinical trials. Any online sellers claiming to offer retatrutide are selling unregulated, unverified products. We strongly advise against purchasing unapproved investigational drugs from any source.
Not Willing to Wait Years?
Retatrutide is still a few years from the pharmacy counter — but GLP-1 treatments with real-world track records are prescribable right now. Compare vetted providers and find the option that fits your weight loss goals today.